Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico.
Conclusion: Outcomes of w-AIHA treatment were considerably heterogeneous. Low rituximab doses plus high dexamethasone doses were effective for refractory disease.
PMID: 31309092 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research
More News: Anemia | Autoimmune Disease | Dexamethasone | Hematology | Mexico Health | Rituxan | Women